|
Market Closed -
NYSE
00:00:03 28/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 18.14 USD | +2.14% |
|
-23.62% | -23.88% |
| 10-22 | Arcus Biosciences Prices $250 Million Common Stock Offering; Shares Down Pre-Bell | MT |
| 10-21 | Wedbush Adjusts Price Target on Arcus Biosciences to $49 From $43, Keeps Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 2.61B | - | ||||
| 63.48B | |||||
| 54.55B | |||||
| 53.59B | |||||
| 44.75B | |||||
| 41.62B |
Select your edition
All financial news and data tailored to specific country editions
